Personalized health care for men and women: testosterone replacement therapy (TRT), GLP-1 weight loss, wellness and longevity treatments in White Plains and Garden City, NY
New work offers evidence that the shots actually provide long-lasting benefits
The same ask your doctor or pharmacist first caution that applies to conventional medications on this page is the safest default for herbs too, especially ones known to affect gut motility
Because the cause of secondary coenzyme Q 10 in inherited conditions is generally unknown, it is difficult to predict whether improving coenzyme Q 10 status with supplemental coenzyme Q 10 would lead to clinical benefits for the patients
(2025) GLP-1 Receptor Agonist Medications for Obesity and Type 2 Diabetes Treatment: A Rapid Review of Changes in Eating Behaviors and Eating Disorder Risk, Obesity Reviews Advocacy and Clinical Organizations National Eating Disorders Association (NEDA) GLP-1 Medications and Eating Disorders ANAD GLP-1 Medications & Eating Disorders Clinical and News Sources Medscape (April 2025) GLP-1 RAs in Eating Disorders: Promising or Perilous? NPR (February 2026) GLP-1 obesity drugs and eating disorders are not well understood yet National Geographic (November 2025) Doctors are worried about prescribing GLP-1s to certain patients NBC News (August 2024) Eating disorders rise amid popular weight loss medications Wegovy and Zepbound
00967-0/asset/1cda1e69-507e-47d1-ad73-620bcd1cbb66/main.assets/gr2_lrg.jpg)
Zepbound (tirzepatide) is a glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptor agonist that is FDA-approved along with increased physical activity and a reduced-calorie diet for chronic weight management in adults with a starting body mass index (BMI) of: 30 kg/m^2 or higher (obesity) 27 kg/m^2 or higher (overweight) with at least one weight-related condition such as high cholesterol, high blood pressure (hypertension), type 2 diabetes, heart disease, or obstructive sleep apnea
